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ABSTRACT 
Neuroinflammation may have beneficial or detrimental net effects on the cognitive 
outcome of Alzheimer’s disease (AD) patients. 18kDa translocator protein (TSPO) 
imaging by positron-emission-tomography (PET) enables longitudinal monitoring of 
microglial activation in vivo. We compiled serial PET measures of TSPO and amyloid 
with terminal cognitive assessment (water maze) in an AD transgenic mouse model 
(PS2APP) from eight to 13 months of age, followed by immunohistochemical analyses of 
microglia, amyloid and synaptic density. Better cognitive outcome and higher synaptic 
density in PS2APP mice was predicted by higher TSPO expression at eight months. The 
progression of TSPO activation to 13 months also showed a moderate association with 
spared cognition, but amyloidosis did not correlate with the cognitive outcome, 
regardless of the timepoint. This first PET investigation with longitudinal TSPO- and 
amyloid-PET together with terminal cognitive testing in an AD mouse model indicates 
that continuing microglial response seems to impart preserved cognitive performance. 
Key words: Amyloid-PET; TSPO-PET; synaptic density; neuroinflammation; water maze  
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INTRODUCTION 
Alzheimer’s disease (AD) is the most common cause of dementia, and is placing 
an ever more onerous burden on health care due to its exponentially rising incidence 
with increasing age (1). Immunologically-mediated neuroinflammation is one hallmark of 
the pathophysiological process of AD (2,3). Current models view neuroinflammation as a 
double-edged sword, which can have protective or detrimental effects on brain 
pathology, function and the cognitive outcome (4,5). Microglia, the resident phagocytes 
of the innate immune system in the central nervous system continuously survey for 
pathogens or cellular debris, secrete factors for tissue repair and contribute to plasticity 
of neuronal circuits by supporting the maintenance and remodeling of synapses (6). 
Microglia in AD brain can recognize and phagocytose soluble and fibrillary β-amyloid 
(Aβ), resulting in an increased inflammatory reaction (2). While this kind of acute 
inflammation response promotes cellular repair and restores brain integrity, chronic 
inflammation processes can contribute to neurodegeneration (7).   
Various transgenic mouse models of AD recapitulate neuroinflammatory 
processes in conjunction with classical β-amyloid pathology (8,9); and translational 
studies of these models are facilitated by small animal positron-emission-tomography 
(PET) with radioligands for imaging of AD biomarkers (10,11). The 18kD translocator 
protein (TSPO), which is highly expressed at the outer mitrochondrial membrane of 
activated microglia, presents a valuable biomarker for autoradiographic studies of 
microglial activation (12,13), and likewise for examination by PET of neuroinflammation 
in brain of AD patients or in AD mouse models (14).  
PET investigation of AD patients indicated only low correlation between cerebral 
amyloid burden and cognitive performance (15), and Aβ deposition precedes the onset 
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of neuroinflammation in patients with mild cognitive impairment (16). We contend that 
the temporal sequences of Aβ deposition and microglial activation in relation to 
progression of cognitive impairments is best examined through molecular imaging 
studies of longitudinal design. We have established this principle in serial PET 
examinations of Aβ accumulation in PS2APP mice treated with an experimental γ-
secretase inhibitor (17).  
Given this background, we aimed now to correlate serial measures of TSPO- and 
β-amyloid-PET (Aβ-PET) with the terminal cognitive assessment in the PS2APP amyloid 
mouse model. Our goals were as follows: (1) Assessment of possible correlations 
between fibrillar amyloidosis in young and aged PS2APP mice with the cognitive 
outcome; (2) Determine if early microglial response at baseline has an impact on the 
terminal cognitive outcome; (3) Determine if ongoing microglial activation influences the 
terminal cognitive outcome. 
 
MATERIALS AND METHODS 
Study Design 
All experiments were performed in compliance with the National Guidelines for 
Animal Protection, Germany, with approval of the local animal care committee of the 
Government of Oberbayern (Regierung Oberbayern), and overseen by a veterinarian. 
The study was performed in a longitudinal design starting with dual tracer PET (TSPO 
and Aβ) at eight months of age as the first time-point (TP-1). Additional TSPO-PET was 
acquired at 9.5 months (TP-2), 11.5 months (TP-3) and 13 months (TP-4) of age, while a 
final Aβ-PET examination was performed at TP-4. After the recovery from the last PET 
scan, mice were transferred to the behavioral facility and rested for one week before 
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initiation of the water maze (WM) tests of spatial learning. One week after behavioural 
test mice were deeply anaesthetized prior to transcardial perfusion. After brain 
extraction, we processed the brains for immunohistochemical and biochemical analyses 
(randomized hemispheres). Fig. 1 illustrates the study design. 
Insert Fig.1 
 
Animal Models and Statistical Power Analysis 
We used seven female wild-type C57Bl/6 (WT) and ten PS2APP transgenic mice 
(TG) in this investigation (18,19). Required sample sizes were calculated for correlation 
analyses (TG) and group comparisons (TG vs. WT) using G*power (V3.1.9.2, Kiel, 
Germany), based on assumptions for a type I error α=0.05 and a power of 0.8. Effect 
size estimations were based on previous investigations with the same model. One 
additional animal was included per genotype to account for possible drop-outs.  
 
PET Imaging 
     PET Acquisition, Reconstruction and Post-Processing: All PET procedures followed 
an established standardized protocol for radiochemistry, acquisition and post-processing 
(14,20). In brief 18F-GE180 TSPO-PET (11.2±1.5 MBq) with an emission window of 60-
90 min p.i. was used to measure cerebral TSPO expression, and 18F-florbetaben Aβ-
PET (10.8±1.5 MBq) with an emission window of 30-60 min p.i. was used for 
assessment of fibrillary cerebral amyloidosis. All analyses were performed by PMOD 
(V3.5, PMOD technologies, Basel, Switzerland). Normalization of images to 
standardized-uptake-value(-ratio) (SUV(R)) images was performed by the previously 
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validated myocardium correction method (21) for TSPO-PET and by a white matter 
reference region for Aβ-PET (20). 
     PET Image Analysis: Standard deviation images (Z-score) were generated for all 
PS2APP mice for all time points and for both tracers. Here we used age-matched WT 
images specific (N=7 each) to calculate maps of average (AVGWT) and standard 
deviation (SDWT) of the relative SUVR for each tracer. Calculation of individual PS2APP 
Z-score images was performed by the formula (PS2APP - AVGWT)/SDWT. Voxel-wise 
maps for the area under the curve (AUC) of tracer uptake differences were calculated for 
each individual animal by generation/summation of Z-score averages between imaging 
time points weighted for the respective time gap. The following equations were used: 
Eq.1: TSPO-PET AUC=6• TP1+TP22 +8•	
TP2+TP3
2 +6•
TP3+TP4
2   
Eq.2: Aβ-PET AUC=20• TP1+TP42  
Voxel-wise correlation analyses of Z-score and AUC maps with behavioral results 
were performed by statistical parametric mapping (SPM) using SPM5 routines 
(Wellcome Department of Cognitive Neurology) implemented in MATLAB (version 7.1; 
MathWorks Inc.). For volume-of-interest (VOI)-based analyses we applied two 
predefined VOIs: 1) A large forebrain VOI comprising mainly neocortical and 
hippocampal regions with highest amyloidosis in PS2APP mice (92mm³). 2) The second 
VOI comprised brain areas associated with spatial learning including the hippocampal 
formation, piriform and entorhinal cortices as well as the amygdala (32mm³). 
Additionally, VOIs of peak clusters deriving from the SPM analysis were applied for 
extraction of individual regional Z-score values. Correlation analysis of VOI-based Z-
score PET values with other modalities was performed by calculating Pearson’s 
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coefficient of correlation. 
 
Water Maze 
Mice were subjected to a modified WM task as described previously (22-24) 
yielding escape latency and distance to the correct platform as read outs. 
Mice had to distinguish between two visible platforms, one of which was weighted 
in a way that it would float when the mouse climbed on (correct choice), while the other 
would sink (wrong choice). The correct platform was always located at the same spot in 
the maze, while the wrong platform as well as the site from which the mice were 
released into the maze was varied in a pseudorandom fashion. Visual cues on the walls 
of the laboratory provided orientation. Trials were terminated if the mouse had failed to 
reach one of the platforms within 30 sec (error of omission). In this case, or in case of a 
wrong choice, the experimenter placed the mouse on the correct platform. After a three-
day handling period, WM training was performed on five consecutive days, with five 
trials per day, which were conducted 2-4 minutes apart. Memory performance was 
assessed by measuring the escape latency at each day of training and by the travelled 
distance at the last training day. For escape latency we calculated the summed average 
time of all trials from the start point to attaining one of the platforms. To generate as 
robust values as possible for individual PS2APP mice, we calculated the Z-score 
difference for both methods in contrast with mean WT mouse scores ((PS2APP - 
AVGWT) / SDWT) and built a summed Z-score for each mouse. On the sixth day, the right 
platform was placed in the opposite quadrant of the maze to confirm that the mice had 
used spatial cues rather than rule-based learning to find it. Trials were filmed with a 
video camera and the swimming trace was extracted using custom written LabView 
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software (National Instruments). The experimenter was blind accordingly to the 
phenotype of the animals. 
 
Immunohistochemistry and Biochemistry 
Immunohistochemistry in brain regions corresponding to PET was performed for 
fibrillar Aβ (methoxy-X04), microglia (Iba1), and synaptic density (VGLUT1) as 
previously established (25,26). Assessment of soluble Aβ assessment was performed 
as previously published (27). 
 
Statistics 
IBM SPSS Statistics (V24.0; Chicago, IL) was used for statistical tests. Normal 
distribution of data was verified by the Kolmogorov-Smirnov test. Escape latency 
deriving from the WM test was compared between PS2APP and WT mice by a linear 
mixed model design including all days of training. Distance values deriving from the last 
day of training were compared between PS2APP and WT mice by an unpaired Student’s 
t-test. Pearson’s coefficients of correlation (R) were calculated between WM Z-Score 
values of PS2APP mice and their corresponding terminal Z-Scores deriving from PET 
(Aβ and TSPO), immunohistochemistry (Iba1 and methoxy-X04) quantitation, and 
biochemical levels of soluble Aβ. Voxel-wise and VOI based correlation analyses of 
baseline and serial PET measures with WM Z-Scores were conducted in SPM as 
described above. VGLUT1 quantification in different brain regions of PS2APP and WT 
mice was compared by an unpaired Student’s t-test. R values were calculated for the 
correlation between WM Z-Score values of PS2APP mice and their corresponding 
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VGLUT1 quantification. A threshold of p<0.05 was deemed significant for rejection of the 
null hypothesis. 
 
RESULTS  
Microglial Activity, Amyloidosis and Cognitive Performance in PS2APP Mice 
TSPO-PET examination of PS2APP mice indicated an inverted U-shape from 
eight to 13 months of age with peak at 11.5 months for microglial activation and Aβ-PET 
showed the expected strong increase of amyloidosis from eight to 13 months of age 
(Figs. 2A and 2B). This increase was most pronounced in the frontal and parietal cortex 
as well as in the hippocampus and the thalamus. Microgliosis was strongest in the 
cortex and the hippocampus, but additionally in subcortical regions devoid of Aβ like the 
striatum, entorhinal and piriform cortices. Behavioral testing by WM showed that 
PS2APP mice had cognitive impairment, as revealed by increased escape latency 
(F(1,15)=35.1, p<0.001) and +436% higher travelled distance (p<0.01) compared to WT 
mice (Fig.2C). There was no difference in speed between PS2APP and WT mice. 
Insert Fig.2 
 
Association of Multimodal Terminal Read Outs with Cognitive Performance 
Next, we asked if terminal read outs of PET or immunohistochemistry correlate 
with the cognitive performance in PS2APP mice at 13.5 months of age. The WM 
performance did not show any correlation with Aβ-PET signal in the forebrain and in 
areas specifically associated with spatial learning one week earlier (both R<±0.3; Fig. 
3A). On the other hand, there were trends towards better cognitive performance in mice 
with the highest TSPO-PET signal in forebrain (R=-0.46, P=0.18; Fig. 3A) or in the areas 
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associated with spatial learning (R=-0.51, P=0.13). Immunohistochemistry confirmed in 
vivo findings: Methoxy-X04 quantification of fibrillar Aβ did not indicate an association 
with cognitive performance (R<0.3 Fig. 3A), whereas quantitation of Iba1 
immunostaining showed a significant negative association between microglial activation 
and WM test scores (R=-0.77, P=0.01; Fig. 3A). Multimodal findings in representative 
mice with good and poor WM performance are illustrated in Figs. 3B and 3C. 
Insert Fig.3 
Furthermore, we saw only a weak correlation between biochemical assays of soluble Aβ 
and cognitive performance in TG mice (R=-0.36, P=0.30). 
 
Prediction of Cognitive Performance by Serial PET Imaging 
We undertook longitudinal in vivo observations of amyloidosis and microglial 
activity by PET to test if early or cumulative alterations over time of the pathology 
biomarkers predicted the cognitive outcome of PS2APP mice. We find that better 
cognitive performance is strongly associated with microglial activation five months earlier 
in forebrain (R=-0.71, P<0.05; Fig. 4A) and especially in cognition-associated areas (R=-
0.82, P<0.01; Fig. 4B). Peak clusters of the amygdala, the entorhinal cortex, and the 
hippocampus as identified by SPM, gave especially strong regional correlations of high 
earlier microglial activity and better cognitive performance (R=-0.95, P<0.001; Fig. 4C). 
Statistical maps of the correlation between voxelwise microglial activity and WM 
performance revealed a pattern with strongest association in brain areas involved in 
spatial learning networks, i.e.  the hippocampal formation, the thalamus, and the frontal 
neocortex (28) (Fig. 4D). There were no brain regions showing a negative correlation 
between TSPO-PET at baseline and better terminal cognitive performance. 
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Insert Fig.4 
We had predicted an opposite relationship for cumulative TSPO-PET values over 
time during the whole five months imaging period, since chronic activation of microglia 
could damage synapses, leading to neurodegeneration (7). However, we still observed 
the same positive correlation, meaning that high AUCs of microglial activity were 
associated with a better cognitive performance (Supplemental Figs. 1A-C). Correlations 
between AUCs of microglial activity and WM performance were weaker when compared 
to TSPO-PET findings at baseline, but the spatial pattern of regions related to spatial 
learning networks was even better demarcated (Supplemental Fig. 1D). No brain region 
indicated a significant association between lower longitudinal AUCs of microglial 
activation and better terminal cognitive performance. There were no relevant 
associations of the Aβ-PET signal at baseline or by longitudinal AUC analysis of 
amyloidosis with the terminal cognitive performance. 
Finally, we asked if there is a molecular correlate of the associations between 
microglial activation over time and the terminal cognitive performance. Our terminal 
immunohistochemical analyses of synaptic density showed clear reductions of VGLUT1 
in the dentate gyrus and the frontal cortex of PS2APP mice when compared to WT at 14 
months of age (Fig. 5A). Reductions of VGLUT1 in individual PS2APP mice had a 
moderately strong correlation with behavioral assessment of cognition (Fig. 5B; R=-0.53; 
p=0.12 each). Even more importantly, we also observed that baseline TSPO-PET 
predicted synaptic density measured five months later in the dentate gyrus (R=0.71; 
p<0.05) and the frontal cortex (R=0.57; p<0.1; Fig. 5B and 5C). Thus, we find that an 
early microglial response to amyloid pathology in PS2APP TG mice protects synaptic 
density at follow-up. 
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Insert Fig.5 
 
DISCUSSION  
This preclinical investigation exploits the advantages of serial PET for monitoring 
disease progression in an amyloid transgenic mouse model of AD. For the first time, we 
report longitudinal TSPO- and Aβ-PET findings in conjunction with terminal behavioral 
testing and histological/biochemical examination to depict associations between 
longitudinal amyloidosis and neuroinflammation with cognitive outcome in an 
Aβ/presenilin mouse model of AD. We find that high microglial activation at the onset of 
amyloidosis predicts for better cognitive performance in PS2APP mice at follow-up five 
months later, when Aβ pathology is extensive. Interestingly even longitudinally persistent 
and terminal elevation of microglial activity were associated with a better cognitive 
outcome at the end of the trial. On the other hand, early and longitudinal amyloidosis did 
not predict cognitive outcome and terminal assessments, nor was there any association 
between amyloidosis and cognition. Multimodal immunohistochemical and biochemical 
assessments of microglia, amyloidosis and synaptic density validated and extended the 
in vivo molecular imaging results.  
Neither longitudinal Aβ-PET nor terminal immunohistochemistry for detection of 
fibrillar amyloidosis showed an association with the cognitive performance in individual 
PS2APP mice. Similarly, quantitative markers of β-amyloid had only weak correlations 
with cognition in aged humans (15). This seeming dissociation has been attributed to 
very early onset of fibrillary amyloidosis in AD, with attainment of a plateau level of 
amyloidosis in most patients by the time that cognitive deterioration has declared itself 
(29). Indeed soluble fragments of Aβ might be the culprit toxic agents responsible for 
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synaptic damage and cognitive deterioration (30), whereas fibrillar Aβ could represents 
an inert reservoir. Nonetheless, we did not find any correlation between terminal soluble 
Aβ concentration in brain extracts and cognitive performance in our PS2APP mice at 14 
months of age. Likewise, a recent review of different transgenic mouse models of AD did 
not find a significant overall correlation between soluble or insoluble levels of Aβ and 
cognitive function (31). In this regard, the brain levels of soluble Aβ may vary over time 
due to their dynamic turnover, which hampers the interpretation of results obtained at a 
single time point. We suppose that serial monitoring of soluble Aβ in cerebrospinal fluid 
over time might reveal more meaningful relationships with the terminal cognitive 
outcome. The present data do not support a link between progression of amyloidosis to 
Aβ-PET and the cognitive performance in individual PS2APP mice, which is in line with 
the conclusions of the aforementioned review (31).  
Most importantly, we find a clear benefit of early and longitudinal microglial 
activation to TSPO-PET on the cognitive outcome in this cohort of PS2APP mice (Figs. 
3 and 4). This finding in vivo was supported by immunohistochemical analysis showing 
that the magnitude of synaptic density loss in TG mice relative to WT was moderated by 
an early and ongoing microglial response. We also saw some evidence for an 
association between more pronounced stronger terminal neuroinflammation at 14 
months and better preservation of cognitive function (Fig. 2). At first glance, our findings 
seem at odds with findings of neuronal dysfunction arising from exposure of neurons to 
pro-inflammatory mediators during chronic microglial activation (7). However, not all 
microglia are equal, and it remains a question about specifically what activation state of 
microglia an elevated TSPO-PET signal or Iba1 immunohistochemistry actually reveals. 
There are some hints that elevated TSPO expression is associated with a CD86-positive 
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pro-inflammatory microglia phenotype (32). Nonetheless, the authors of that study also 
observed co-localization of TSPO immunostaining with CD206-positive anti-
inflammatory microglia near amyloid plaques, which could indicate microglial 
phagocytosis of toxic Aβ (33). Clearance of accumulating debris like misfolded proteins 
is indeed a crucial function of anti-inflammatory microglia in their role of protecting brain 
tissue homeostasis (7). Interventional studies with, for example, PPARγ agonists to 
modify microglial phenotype, along with serial microglia monitoring and behavioral 
testing, might address this question in more detail (34). From the current data, it 
emerges that early microglial activation ameliorates the cognitive decline in PS2APP 
mice (Fig. 3). Thus, it seems an essential aspect of the innate immune system that it can 
respond to the developing amyloidosis caused by the genetic modification of the mouse 
model. The net beneficial effect of longitudinal microglial activation on cognitive function 
might be a matter of duration, as synapses will ultimately suffer from excessive exposure 
to pro-inflammatory cytokines. Thus, present protective effect of elevated microglial 
activity on cognitive function in PS2APP mice might have turned into deterioration at 
times after 14 months. 
Another possible explanation for contradictory findings in studies on 
neuroinflammation and subsequent cognitive outcome might be attributable to differing 
mechanistic approaches. Most such investigations used mice with specific manipulations 
of genes involved in inflammatory pathways of AD and tested against WT data. We took 
advantage of the known phenotype heterogeneity of the PS2APP mouse (35) to study 
associations of biomarkers and the terminal cognitive performance in individual mice of 
the same genotype. Our findings imply that a strong magnitude of microglial activation is 
probably necessary to cope with the characteristically heavy Aβ deposition in these mice 
by E-Library Insel on January 31, 2019. For personal use only. jnm.snmjournals.org Downloaded from 
15 
 
(14). This conception fits our current findings of preserved cognitive performance in mice 
with an early microglial response. As an explanation for this phenomenon, we invoke the 
recent description of two peaks of microglial activation in the time course of human 
sporadic AD, one occurring in the pre-symptomatic stage during early amyloid build-up 
and the other presenting in the dementia stage (36). Amyloid mouse models have little 
neuronal loss, and more closely mimic primarily pre-symptomatic and mild-cognitive-
impairment stages of human AD (27). Taken together, our preclinical data support the 
speculation of an early protective peak of microglial activation during initial amyloid 
aggregation (36). Since PS2APP mice show their peak of microglial activation at 
approximately 11.5 months (Fig. 1), we speculate that they may lack a  second peak, as 
they do not show much progression of neuronal loss even at very late stages >16 
months of age (18). 
The main strength of PET lies in its potential to monitor disease-related 
alterations and interventions over time in an individual. Our present findings are 
encouraging for longitudinal PET monitoring of microglial activation in human AD, as 
was recently performed with a first generation TSPO ligand (36). A longitudinal design 
would enable successive correlation of molecular imaging with cognitive deterioration 
over time. We suppose that appropriate modulation of microglial activation according to 
disease stage may lead to interventions with some efficacy. A second main advantage 
of PET lies in spatial mapping of molecular markers in the whole brain. For the first time, 
we have generated 3-dimensional maps of microglial activity over time in individual mice 
(AUC maps), and used these maps for a statistically-based voxel-wise correlation 
analysis with cognitive outcome parameters. Statistical testing of SPM-defined regions 
should be interpreted with care, but our analyses also clearly showed an enhanced 
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association between PET measures of microgliosis in predefined brain regions linked to 
spatial learning with preserved cognition (28). This methodological innovation provides 
the basis for designing intervention studies with endpoints relevant to human AD. 
 
CONCLUSION 
Early microglial response predicts an improved cognitive outcome in PS2APP 
mice, whereas the magnitude of fibrillar amyloidosis in early disease stages is not 
predictive of cognitive performance five months later. These findings emphasize the 
importance of biomarkers for serial monitoring of microglial activity in AD. Furthermore, 
results suggest than the innate immune system could constitute a more relevant 
therapeutic target than amyloidosis regarding the primary objective of preserving 
cognitive performance.  
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Figures 
 
Fig.1: Schematic illustration of the study design and timeline. We obtained a series of 
dual tracer PET scans (TSPO and Aβ) in mice between 8 and 13 months of age. After 
the final scan, we administered behavioural testing by the water maze (WM), followed by 
transcardial perfusion with 4% paraformaldehyde and brain extraction for histochemical, 
immunohistochemical and biochemical analyses.  
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Fig.2: Longitudinal TSPO- and Aβ-PET and performance in behavioural testing. (A) 
Cortical TSPO-PET and Aβ-PET signal intensities of PS2APP mice at different ages are 
expressed as Z-Scores relative to findings in age-matched C57BL/6 mice. Coronal and 
axial slices are projected upon a T1w MRI template. (B) Progression of individual TSPO-
PET Z-Scores and Aβ-PET Z-Scores in the forebrain of PS2APP mice (n=10) with age. 
(C) Differences between PS2APP and C57Bl/6 (WT) mice for escape latency (sec) and 
travelled distance in pixels (pix) as water maze read outs. Error bars represent SEM. 
*p<0.005; **p<0.001. 
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Fig.3: Multimodal correlation analysis of cognitive testing with terminal PET and 
immunohistochemical results in PS2APP mice at study termination. (A) Scatter plots 
show correlations between individual cognitive testing in the water maze task (WM, Z-
score) with terminal PET and immunohistochemistry read outs. Representative PET 
images (Z-Score upon an MRI template), immunohistochemistry (fused methoxy-X04 
(blue) and Iba1 (red)) and WM findings of individual mice, showing either low (B, orange) 
or high (C, magenta) markers of microglial activation at study termination. 
Corresponding data points in A are depicted in orange (#1, low markers of microglial 
activity) and magenta (#2, high markers of microglial activity). R indicates Pearson’s 
coefficient of correlation. *p<0.05 
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Fig.4: Prediction of cognitive performance by the magnitude of microglial activation at 
baseline in PS2APP mice. Correlations between individual findings in cognitive testing 
(Z-scores) with TSPO-PET at baseline are presented by scatter plots for (A) the 
forebrain, (B) brain regions associated with spatial learning, and (C) an amygdaloidal 
peak cluster. (D) Coronal slices depict statistical maps (T-Scores) of voxel-wise 
correlation between TSPO-PET at baseline and performance in water maze (WM) at 
study termination upon a T1w MRI template. R indicates Pearson’s coefficient of 
correlation. *p<0.05; **p<0.01; ***p<0.001 
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Fig.5: Moderation of the reductions of synaptic density in PS2APP mice by early 
microglial response. (A) Reduction in synaptic density (VGLUT1) in PS2APP mice when 
compared to WT. (B) Scatter plots show correlation of individual VGLUT1 alterations, 
cognitive testing and TSPO-PET at baseline in the dentate gyrus and the frontal cortex 
of PS2APP mice. (C) Findings of synaptic density (VGLUT1) in a representative C57Bl/6 
WT mouse (grey), together with two PS2APP mice, one indicating severe VGLUT1 loss 
(#1,orange) and one indicating only minor VGLUT1 loss (#2,magenta). Corresponding 
data points are high-lighted in (B). R indicates Pearson’s coefficient of correlation. Error 
bars represent SEM. #p<0.1; * p<0.05. Scale bar represents 5µm. 
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Supplemental Figure 1. Prediction of cognitive performance by the longitudinal magnitude 
of microglial activation in PS2APP mice. Correlations between individual findings in cognitive 
testing (Z-scores) with longitudinal TSPO-PET ([18F]GE180) as expressed by the area under the 
curve (AUC) are presented by scatter plots for (A) the forebrain, (B) brain regions associated with 
spatial learning, and (C) an amygdaloidal peak cluster. (D) Coronal slices depict statistical maps 
(T-Scores) of voxel-wise correlation between TSPO-PET ([18F]GE180) at baseline and 
performance in water maze (WM) at study termination upon a T1w MRI template. R indicates 
Pearson’s coefficient of correlation. *p<0.05 
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